Phase 3
Completed N=402
Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients
Source: ClinicalTrials.gov NCT01156012 ↗Enrolled (actual)
402
Serious AEs
1.5%
Results posted
Nov 2014
Primary outcomePrimary: Change From Baseline in Intraocular Pressure (IOP) — -8.6; -9.0 mmHg
Summary
The purpose of this study is to assess the efficacy and safety of T2345 versus active comparator.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Intraocular Pressure (IOP) |
-8.6; -9.0 | — |
Eligibility Criteria
Inclusion Criteria
- Adult patients diagnosed with glaucoma
Exclusion Criteria
- Under 18.
Data sourced from ClinicalTrials.gov (NCT01156012). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.